Trial Profile
Feasibility study of a postoperative adjuvant chemotherapy which performs the maintenance therapy of TS-1 after CBDCA+TS-1 to the patients of pathological stage II-IIIA with completely resected non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2013
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Escargot-001
- 02 Sep 2013 Status changed from not stated to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 16 Sep 2011 New trial record